Adenovirus Vaccines - PaxVax

Drug Profile

Adenovirus Vaccines - PaxVax

Alternative Names: Adenovirus Type 4 and Type 7 Vaccine [A549 Cells] - PaxVax; Modernized Production Adenovirus Vaccine - PaxVax; MPAV Prototype A; MPAV Prototype B; PXVX 0047

Latest Information Update: 30 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PaxVax
  • Developer PaxVax; Walter Reed Army Institute of Research
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Adenovirus infections

Most Recent Events

  • 08 May 2017 Preclinical trials in Adenovirus infections in USA (PO, Type 4 and 7 adenoviruses in a capsule)
  • 01 May 2017 Phase-I clinical trials in Adenovirus infections (In volunteers) in USA (PO, Type 4 and 7 adenoviruses in two separte capsule) (NCT03160339)
  • 21 Sep 2015 PaxVax receives phase II SBIR grant from United States Department of Defence for development of adenovirus type 4 and 7 vaccine in Adenovirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top